Universe Pharmaceuticals (UPC) Accumulated Depreciation & Amortization (2021 - 2025)
Universe Pharmaceuticals (UPC) has disclosed Accumulated Depreciation & Amortization for 5 consecutive years, with $6.9 billion as the latest value for Q3 2025.
- Quarterly Accumulated Depreciation & Amortization rose 3.59% to $6.9 billion in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $6.9 billion through Sep 2025, up 3.59% year-over-year, with the annual reading at $6.9 billion for FY2025, 3.59% up from the prior year.
- Accumulated Depreciation & Amortization hit $6.9 billion in Q3 2025 for Universe Pharmaceuticals, up from $6.7 billion in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $6.9 billion in Q3 2025 to a low of $5.7 million in Q3 2022.
- Historically, Accumulated Depreciation & Amortization has averaged $2.7 billion across 5 years, with a median of $6.1 million in 2023.
- Biggest five-year swings in Accumulated Depreciation & Amortization: dropped 1.21% in 2022 and later skyrocketed 110052.67% in 2024.
- Year by year, Accumulated Depreciation & Amortization stood at $5.8 million in 2021, then decreased by 1.21% to $5.7 million in 2022, then increased by 5.96% to $6.1 million in 2023, then surged by 110052.67% to $6.7 billion in 2024, then grew by 3.59% to $6.9 billion in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for UPC at $6.9 billion in Q3 2025, $6.7 billion in Q3 2024, and $6.1 million in Q3 2023.